Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit Unveils Genomics Tool Employing DATAS


PARIS--ExonHit Therapeutics, the inventor of a gene profiling technology called Differential Analysis of Transcripts Alternatively Spliced, has introduced a predictive toxicology tool to enhance pharmaceutical and agrochemical research and development. Safe-Hit is a nucleic acid array that incorporates a library of genetic signaturesselected for being affected when cells and tissues are subjected to toxic stresses. A software module in the product reads the microarray, interprets results, and ranks compounds by toxicity.

According to the company, Safe-Hit works with alterations of transcripts, including gene splicing, obtained from a sustained expression of the wild-type p53 protein. The software is the first of a series of products based on the DATAS technology. Bruno Tocque, the company's CEO, said, "It is about time that genomics delivers in the field of toxicology, and Safe-Hit does just that." He called it a "complete product that will go a long way to taking the scientist's hunch out of lead molecule selection."

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.